Work Here?
Twist Bioscience
Work Here?
Produces synthetic DNA for biotechnology applications
Twist Bioscience
Work Here?
Produces synthetic DNA for biotechnology applications
About Twist Bioscience
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2013
Overview
Twist Bioscience focuses on synthesizing synthetic DNA for applications in biotechnology, pharmaceuticals, and research. Their proprietary platform allows for quick and accurate production of DNA sequences, providing clients with products like genes, oligo pools, and variant libraries. The company stands out by offering high-quality DNA at competitive prices, making it a valuable partner for academic and pharmaceutical clients. Twist Bioscience aims to lead in the synthetic biology market by rapidly delivering complex DNA sequences to support scientific advancements.
Simplify's Take
What believers are saying
- Growing demand for synthetic DNA in personalized medicine boosts Twist's market potential.
- Collaboration with Absci leverages AI to accelerate antibody discovery and drug development.
- Synthetic biology market projected to grow at 28.8% CAGR, benefiting Twist's growth.
What critics are saying
- Increased competition from Ginkgo Bioworks may impact Twist's market share.
- Dependency on AI technologies could pose integration and operational challenges.
- New CIO appointment may lead to transitional challenges in IT strategy and operations.
What makes Twist Bioscience unique
- Twist Bioscience uses a unique silicon-based DNA synthesis platform for precision and scale.
- They offer high-quality DNA sequences at competitive prices, attracting diverse clients.
- Their proprietary platform provides instant feedback on DNA sequence synthesis feasibility.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$623.1M
Above
Industry Average
Funded Over
9 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
401(k) Retirement Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -1%Twist Bioscience named a Best Idea for 2025 at TD Cowen.
Absci, a pioneer in generative AI-driven drug discovery, and Twist Bioscience, a leader in high-quality synthetic DNA production through its silicon platform, have announced an innovative collaboration to create a novel therapeutic antibody using generative AI.
In other recent news, Twist Bioscience has secured a $15 million capital boost from a new financial agreement with XOMA Royalty Corporation.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator.
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer.
Twist Bioscience is Hiring for 27 Jobs on Simplify!
Find jobs on Simplify and start your career today
Customer Experience & Support
1 Open Roles
People Also Viewed
Discover companies similar to Twist Bioscience
About Twist Bioscience
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2013
Twist Bioscience is Hiring for 27 Jobs on Simplify!
Find jobs on Simplify and start your career today
Customer Experience & Support
1 Open Roles
People Also Viewed
Discover companies similar to Twist Bioscience